PRINCETON, N.J. , Aug.
9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024 . "This is a pivotal time for Soligenix with a great deal of clinical activity and upcoming milestones," stated Christopher J.
Schaber, PhD, President and Chief Executive Officer of Soligenix. "While we prepare for the upcoming initiation of our confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte TM (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease, we are incredibly encouraged by the recent positive clinical results from our comparability study evaluating HyBryte TM against Valchlor ® (mechlorethamine gel), which demonstrated a three-fold higher response rate over a 12-week treatment period and more favorable safety profile for HyBryte TM in the treatment of CTCL. These findings, coupled with the promising interim data from the ongoing open-label, investigator-initiated study evaluating extended HyBryte TM treatment, reinforce our excitement about the future of HyBryte TM as a potential front-line treatment option for patients with early-stage CTCL.
Additionally, we will be initiating a Phase 2 study with SGX945 (dusquetide).